Samuel S Dychter
Overview
Explore the profile of Samuel S Dychter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
634
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moreira Jr E, Kitchin N, Xu X, Dychter S, Lockhart S, Gurtman A, et al.
N Engl J Med
. 2022 Mar;
386(20):1910-1921.
PMID: 35320659
Background: Active immunization with the BNT162b2 vaccine (Pfizer-BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease 2019 (Covid-19) pandemic....
2.
Thomas S, Perez J, Lockhart S, Hariharan S, Kitchin N, Bailey R, et al.
Vaccine
. 2022 Feb;
40(10):1483-1492.
PMID: 35131133
Introduction: Individuals with an underlying malignancy have high risk of poor COVID-19 outcomes. In clinical trials, COVID-19 vaccines were safe and efficacious against infection, hospitalization, and death, but most trials...
3.
Pujade-Lauraine E, Fujiwara K, Ledermann J, Oza A, Kristeleit R, Ray-Coquard I, et al.
Lancet Oncol
. 2021 Jun;
22(7):1034-1046.
PMID: 34143970
Background: Most patients with ovarian cancer will relapse after receiving frontline platinum-based chemotherapy and eventually develop platinum-resistant or platinum-refractory disease. We report results of avelumab alone or avelumab plus pegylated...
4.
Printz M, Dychter S, DeNoia E, Harrigan R, Sugarman B, Zepeda M, et al.
Curr Ther Res Clin Exp
. 2020 Sep;
93:100604.
PMID: 32963641
Background: Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/hyaluronidase-zzxf], and Darzalex FASPRO [daratumumab and...
5.
Pujade-Lauraine E, Fujiwara K, Dychter S, Devgan G, Monk B
Future Oncol
. 2018 Mar;
14(21):2103-2113.
PMID: 29584456
Avelumab is a human anti-PD-L1 checkpoint inhibitor with clinical activity in multiple solid tumors. Here, we describe the rationale and design for JAVELIN Ovarian 200 (NCT02580058), the first randomized Phase...
6.
Infante J, Korn R, Rosen L, LoRusso P, Dychter S, Zhu J, et al.
Br J Cancer
. 2018 Jan;
118(2):e3.
PMID: 29361630
This corrects the article DOI: 10.1038/bjc.2017.327.
7.
Infante J, Korn R, Rosen L, LoRusso P, Dychter S, Zhu J, et al.
Br J Cancer
. 2017 Sep;
118(2):153-161.
PMID: 28949957
Background: Hyaluronan accumulation in tumour stroma is associated with reduced survival in preclinical cancer models. PEGPH20 degrades hyaluronan to facilitate tumour access for cancer therapies. Our objective was to assess...
8.
Rosengren S, Dychter S, Printz M, Huang L, Schiff R, Schwarz H, et al.
AAPS J
. 2015 Sep;
17(6):1523-4.
PMID: 26340861
No abstract available.
9.
Rosengren S, Dychter S, Printz M, Huang L, Schiff R, Schwarz H, et al.
AAPS J
. 2015 May;
17(5):1144-56.
PMID: 25967925
Recombinant human PH20 hyaluronidase (rHuPH20) is used to facilitate dispersion of subcutaneously delivered fluids and drugs. This report summarizes rHuPH20 immunogenicity findings from clinical trials where rHuPH20 was co-administered with...
10.
Dychter S, Ebel D, Mead T, Yocum R
Curr Ther Res Clin Exp
. 2014 Apr;
70(6):421-38.
PMID: 24692835
Background: Recombinant human hyaluronidase (rHuPH20) (150 U) is approved by the US Food and Drug Administration to facilitate subcutaneous fluid administration in adults and children. Objective: This Phase IV, double-blind,...